BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 25661440)

  • 1. Fukutin is prerequisite to ameliorate muscular dystrophic phenotype by myofiber-selective LARGE expression.
    Ohtsuka Y; Kanagawa M; Yu CC; Ito C; Chiyo T; Kobayashi K; Okada T; Takeda S; Toda T
    Sci Rep; 2015 Feb; 5():8316. PubMed ID: 25661440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired viability of muscle precursor cells in muscular dystrophy with glycosylation defects and amelioration of its severe phenotype by limited gene expression.
    Kanagawa M; Yu CC; Ito C; Fukada S; Hozoji-Inada M; Chiyo T; Kuga A; Matsuo M; Sato K; Yamaguchi M; Ito T; Ohtsuka Y; Katanosaka Y; Miyagoe-Suzuki Y; Naruse K; Kobayashi K; Okada T; Takeda S; Toda T
    Hum Mol Genet; 2013 Aug; 22(15):3003-15. PubMed ID: 23562821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current status and future prospects of research on Fukuyama muscular dystrophy].
    Toda T
    Nihon Rinsho; 2015 Aug; 73(8):1425-36. PubMed ID: 26281700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of LARGE suppresses muscle regeneration via down-regulation of insulin-like growth factor 1 and aggravates muscular dystrophy in mice.
    Saito F; Kanagawa M; Ikeda M; Hagiwara H; Masaki T; Ohkuma H; Katanosaka Y; Shimizu T; Sonoo M; Toda T; Matsumura K
    Hum Mol Genet; 2014 Sep; 23(17):4543-58. PubMed ID: 24722207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of dysferlin deficiency to skeletal muscle pathology in asymptomatic and severe dystroglycanopathy models: generation of a new model for Fukuyama congenital muscular dystrophy.
    Kanagawa M; Lu Z; Ito C; Matsuda C; Miyake K; Toda T
    PLoS One; 2014; 9(9):e106721. PubMed ID: 25198651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Alpha-dystroglycanopathy (FCMD, MEB, etc): abnormal glycosylation and muscular dystrophy].
    Toda T
    Rinsho Shinkeigaku; 2005 Nov; 45(11):932-4. PubMed ID: 16447766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fukutin expression in mouse non-muscle somatic organs: its relationship to the hypoglycosylation of alpha-dystroglycan in Fukuyama-type congenital muscular dystrophy.
    Saito Y; Yamamoto T; Ohtsuka-Tsurumi E; Oka A; Mizuguchi M; Itoh M; Voit T; Kato Y; Kobayashi M; Saito K; Osawa M
    Brain Dev; 2004 Oct; 26(7):469-79. PubMed ID: 15351084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mislocalization of fukutin protein by disease-causing missense mutations can be rescued with treatments directed at folding amelioration.
    Tachikawa M; Kanagawa M; Yu CC; Kobayashi K; Toda T
    J Biol Chem; 2012 Mar; 287(11):8398-406. PubMed ID: 22275357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Recent Advances in α-dystroglycanopathy].
    Kuga A; Kanagawa M; Toda T
    Brain Nerve; 2011 Nov; 63(11):1189-95. PubMed ID: 22068471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adeno-associated viral-mediated LARGE gene therapy rescues the muscular dystrophic phenotype in mouse models of dystroglycanopathy.
    Yu M; He Y; Wang K; Zhang P; Zhang S; Hu H
    Hum Gene Ther; 2013 Mar; 24(3):317-30. PubMed ID: 23379513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adeno-associated virus-mediated overexpression of LARGE rescues α-dystroglycan function in dystrophic mice with mutations in the fukutin-related protein.
    Vannoy CH; Xu L; Keramaris E; Lu P; Xiao X; Lu QL
    Hum Gene Ther Methods; 2014 Jun; 25(3):187-96. PubMed ID: 24635668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular interaction between fukutin and POMGnT1 in the glycosylation pathway of alpha-dystroglycan.
    Xiong H; Kobayashi K; Tachikawa M; Manya H; Takeda S; Chiyonobu T; Fujikake N; Wang F; Nishimoto A; Morris GE; Nagai Y; Kanagawa M; Endo T; Toda T
    Biochem Biophys Res Commun; 2006 Dec; 350(4):935-41. PubMed ID: 17034757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temporal requirement of dystroglycan glycosylation during brain development and rescue of severe cortical dysplasia via gene delivery in the fetal stage.
    Sudo A; Kanagawa M; Kondo M; Ito C; Kobayashi K; Endo M; Minami Y; Aiba A; Toda T
    Hum Mol Genet; 2018 Apr; 27(7):1174-1185. PubMed ID: 29360985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Residual laminin-binding activity and enhanced dystroglycan glycosylation by LARGE in novel model mice to dystroglycanopathy.
    Kanagawa M; Nishimoto A; Chiyonobu T; Takeda S; Miyagoe-Suzuki Y; Wang F; Fujikake N; Taniguchi M; Lu Z; Tachikawa M; Nagai Y; Tashiro F; Miyazaki J; Tajima Y; Takeda S; Endo T; Kobayashi K; Campbell KP; Toda T
    Hum Mol Genet; 2009 Feb; 18(4):621-31. PubMed ID: 19017726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defective glycosylation of α-dystroglycan contributes to podocyte flattening.
    Kojima K; Nosaka H; Kishimoto Y; Nishiyama Y; Fukuda S; Shimada M; Kodaka K; Saito F; Matsumura K; Shimizu T; Toda T; Takeda S; Kawachi H; Uchida S
    Kidney Int; 2011 Feb; 79(3):311-6. PubMed ID: 20944549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenic exon-trapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophy.
    Taniguchi-Ikeda M; Kobayashi K; Kanagawa M; Yu CC; Mori K; Oda T; Kuga A; Kurahashi H; Akman HO; DiMauro S; Kaji R; Yokota T; Takeda S; Toda T
    Nature; 2011 Oct; 478(7367):127-31. PubMed ID: 21979053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Four-week rapamycin treatment improves muscular dystrophy in a fukutin-deficient mouse model of dystroglycanopathy.
    Foltz SJ; Luan J; Call JA; Patel A; Peissig KB; Fortunato MJ; Beedle AM
    Skelet Muscle; 2016; 6():20. PubMed ID: 27257474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Congenital muscular dystrophy with glycosylation defects of alpha-dystroglycan in Japan.
    Matsumoto H; Hayashi YK; Kim DS; Ogawa M; Murakami T; Noguchi S; Nonaka I; Nakazawa T; Matsuo T; Futagami S; Campbell KP; Nishino I
    Neuromuscul Disord; 2005 May; 15(5):342-8. PubMed ID: 15833426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fukutin and alpha-dystroglycanopathies.
    Toda T; Chiyonobu T; Xiong H; Tachikawa M; Kobayashi K; Manya H; Takeda S; Taniguchi M; Kurahashi H; Endo T
    Acta Myol; 2005 Oct; 24(2):60-3. PubMed ID: 16550916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant neuromuscular junctions and delayed terminal muscle fiber maturation in alpha-dystroglycanopathies.
    Taniguchi M; Kurahashi H; Noguchi S; Fukudome T; Okinaga T; Tsukahara T; Tajima Y; Ozono K; Nishino I; Nonaka I; Toda T
    Hum Mol Genet; 2006 Apr; 15(8):1279-89. PubMed ID: 16531417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.